- Home
- SOLV vs PCVX Comparison
SOLV vs PCVX Comparison
Compare SOLV & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOLV
- PCVX
- Stock Information
- Founded
- SOLV 2023
- PCVX 2013
- Country
- SOLV United States
- PCVX United States
- Employees
- SOLV N/A
- PCVX N/A
- Industry
- SOLV
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- SOLV
- PCVX Health Care
- Exchange
- SOLV NYSE
- PCVX Nasdaq
- Market Cap
- SOLV 11.5B
- PCVX 13.2B
- IPO Year
- SOLV N/A
- PCVX 2020
- Fundamental
- Price
- SOLV $70.18
- PCVX $78.14
- Analyst Decision
- SOLV Hold
- PCVX Strong Buy
- Analyst Count
- SOLV 10
- PCVX 9
- Target Price
- SOLV $68.29
- PCVX $149.38
- AVG Volume (30 Days)
- SOLV 870.3K
- PCVX 1.1M
- Earning Date
- SOLV 01-28-2025
- PCVX 02-25-2025
- Dividend Yield
- SOLV N/A
- PCVX N/A
- EPS Growth
- SOLV N/A
- PCVX N/A
- EPS
- SOLV 4.16
- PCVX N/A
- Revenue
- SOLV $8,215,000,000.00
- PCVX N/A
- Revenue This Year
- SOLV $2.44
- PCVX N/A
- Revenue Next Year
- SOLV $0.38
- PCVX N/A
- P/E Ratio
- SOLV $16.86
- PCVX N/A
- Revenue Growth
- SOLV 0.60
- PCVX N/A
- 52 Week Low
- SOLV $47.16
- PCVX $58.10
- 52 Week High
- SOLV $77.17
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- SOLV N/A
- PCVX 32.14
- Support Level
- SOLV N/A
- PCVX $80.10
- Resistance Level
- SOLV N/A
- PCVX $81.70
- Average True Range (ATR)
- SOLV 0.00
- PCVX 3.12
- MACD
- SOLV 0.00
- PCVX -0.13
- Stochastic Oscillator
- SOLV 0.00
- PCVX 5.68
About SOLV SOLVENTUM CORP
Solventum Corp is an independent healthcare company with a primary focus on addressing healthcare challenges. Its diverse product portfolio spans the healthcare industry, including medical solutions, oral care, health information systems, and separation and purification sciences.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.